PureTech Health (CHIX:PRTCL) Growth Rank: 7 (As of Aug. 01, 2026) — 133% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:PRTCL PureTech Health PLC CHIX:PRTCL
65 GF Score
Price £1.19
GF Value £5.39
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is PureTech Health Growth Rank?

PureTech Health CHIX:PRTCL -0.67% 65 Growth Rank is 7 as of Aug. 01, 2026, which is 133% above its 10-year median of 3.00. GuruFocus rates CHIX:PRTCL with a GF Score™ of 65/100 and a GF Value™ of £5.39 (Possible Value Trap). The stock has 3 warning signs investors should review.

PureTech Health has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

PureTech Health Growth Rank Related Terms

CHIX:PRTCL vs VRTX, REGN, RVMD: Growth Rank Comparison

For the Biotechnology subindustry, PureTech Health's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PureTech Health Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's Growth Rank distribution charts can be found below:

* The bar in red indicates where PureTech Health's Growth Rank falls into.


CHIX:PRTCL
65GF Score
PureTech Health PLC CHIX:PRTCL
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
PureTech Health (CHIX:PRTCL) has a Growth Rank of 7 as of Aug. 01, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on PureTech Health and its competitors. This is 133% above median its historical median of 3.00. Over the past decade, PureTech Health's Growth Rank has ranged from 1.00 to 7.00.
Is PureTech Health's Growth Rank too high?
PureTech Health's current Growth Rank of 7 is 133% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. Overall, PureTech Health has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Growth Rank compare to VRTX and REGN?
PureTech Health's Growth Rank of 7 can be compared against companies in the Biotechnology industry. Historically, PureTech Health's own Growth Rank has ranged from 1.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on PureTech Health and its competitors. PureTech Health's current Growth Rank is 7, which is 133% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (CHIX:PRTCL) is currently considered Possible Value Trap. The stock's GF Value™ is £5.39, compared to a current price of £1.19 — trading 77.9% below its estimated fair value. The current Growth Rank is 7, which is 133% above median its 10-year median of 3.00. PureTech Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For PureTech Health (CHIX:PRTCL), the current Growth Rank is 7 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PureTech Health (CHIX:PRTCL) Overvalued in 2026?

Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued. The current stock price of £1.19 is trading 77.9% below its estimated GF Value™ of £5.39. GuruFocus considers PureTech Health to be Possible Value Trap.

Key valuation signals for CHIX:PRTCL:

  • Growth Rank: 7 (133% above median its 10-year median of 3.00)
  • GF Value™: £5.39 vs. price of £1.19 (77.9% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the CHIX:PRTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PureTech Health Business Description

Address 6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
65GF Score

Get the complete analysis for CHIX:PRTCL

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.19
Price
£5.39
GF Value